Ziad A Ali, MD

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:45

Article:201

Review Article:32

Comment/Debate:8

Letter:19

Editorial:6

Chapter:1

Recent Artifacts

• Impact of Nonobstructive Left Main Coronary Artery Atherosclerosis on Long-Term Mortality
• Reproducibility of 3D Vessel Fractional Flow Reserve (vFFR): A Core Laboratory Variability Analysis of FAST II Study
• Calcium Modification in Percutaneous Coronary Interventions
• Clinical Utility of Intravascular Imaging: Past, Present, and Future
• Intravascular Lithotripsy for Treatment of Calcified Coronary Artery Disease
• Optical coherence tomography in coronary atherosclerosis assessment and intervention
• Predicting future left anterior descending artery events from non-culprit lesions: insights from the Lipid-Rich Plaque study
• Prevalence and Impact of Neoatherosclerosis on Clinical Outcomes After Percutaneous Treatment of Second-Generation Drug-Eluting Stent Restenosis
• The Bigger the Highway, the Less Likely the Traffic Jam
• Greater plaque burden and cholesterol content may explain an increased incidence of non-culprit events in diabetic patients: a Lipid-Rich Plaque substudy

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Ali during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.